Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126015031 | 12601503 | 1 | I | 20160206 | 20160726 | 20160728 | 20160728 | EXP | FR-ROCHE-1802919 | ROCHE | 65.00 | YR | F | Y | 59.50000 | KG | 20160728 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126015031 | 12601503 | 1 | PS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | Y | 50722 | 1.75 | G | BID | |||||||
| 126015031 | 12601503 | 2 | SS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 500MG IN THE MORNING AND IN THE EVENING. | Y | 50722 | 500 | MG | BID | ||||||
| 126015031 | 12601503 | 3 | SS | RoValcyte | VALGANCICLOVIR HYDROCHLORIDE | 1 | Oral | Y | 21304 | 450 | MG | ||||||||
| 126015031 | 12601503 | 4 | SS | NEORAL | CYCLOSPORINE | 1 | Oral | 0 | |||||||||||
| 126015031 | 12601503 | 5 | C | SOLUPRED (FRANCE) | PREDNISOLONE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 126015031 | 12601503 | 6 | C | KEPPRA | LEVETIRACETAM | 1 | Oral | 0 | 1 | G | BID | ||||||||
| 126015031 | 12601503 | 7 | C | LEVOTHYROX | LEVOTHYROXINE | 1 | Oral | 0 | 50 | UG | QD | ||||||||
| 126015031 | 12601503 | 8 | C | URBANYL | CLOBAZAM | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 126015031 | 12601503 | 9 | C | MIRCERA | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 1 | Intravenous (not otherwise specified) | 0 | 100 | UG | /month | ||||||||
| 126015031 | 12601503 | 10 | C | LASILIX | FUROSEMIDE | 1 | Oral | 0 | 250 | MG | BID | ||||||||
| 126015031 | 12601503 | 11 | C | HEPARINA SODICA | HEPARIN SODIUM | 1 | Intravenous (not otherwise specified) | 0 | 8000 | IU | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126015031 | 12601503 | 1 | Product used for unknown indication |
| 126015031 | 12601503 | 3 | Product used for unknown indication |
| 126015031 | 12601503 | 4 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126015031 | 12601503 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126015031 | 12601503 | Agranulocytosis | |
| 126015031 | 12601503 | Leukopenia | |
| 126015031 | 12601503 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126015031 | 12601503 | 3 | 20160208 | 0 | ||
| 126015031 | 12601503 | 4 | 20160205 | 0 |